On April 30, 2024, GALAPAGOS NV held its Annual and Extraordinary Shareholders’ Meetings, approving financial reports, director remuneration, and appointing new board members. Notably, new warrants for Gilead Therapeutics were approved, allowing equity participation capped at 29.9%.